Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

ESMO 2018 /
Magnetic marker to judge pathological response to checkpoint therapy in melanoma

19th - 23rd Oct 2018

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 20.10.18
Views: 521

Dr Alexander van Akkooi - Netherlands Cancer Institute, Amsterdam, Netherlands

Dr Alexander van Akkooi speaks with ecancer at ESMO 2018 in Munich about a pilot study employing an inserted magnetic marker to help guide lymph node imaging for patients with advanced melanoma who have been treated with nivolumab and ipilimumab.

He highlights the current surgical options which can leave patients with chronic lymphedema, and iodine seeds which expose patients to ongoing radiation.

By comparison, the magnetic marker is effective, well tolerated, and Dr van Akkooi outlines follow-up studies to expand its use.

ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.


· ESMO 2018

Previous conferences: highlights

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation